文献速递母胎医学产科

产前微阵列应用现状:遗传咨询实践与障碍调查

The utilization of prenatal microarray: A survey of current genetic counseling practices and barriers.
PubMed 文献 · Prenat Diagn · 2019-02-28

该调查基于美国妇产科医师学会(ACOG)与母胎医学会(SMFM)指南发布后,评估产前遗传咨询师(GCs)对产前染色体微阵列(CMA)的实践、态度与障碍。192名受访者中183人(95%)已将CMA纳入临床实践,64%认为获益大于风险,52%同意无论指征均应向所有孕妇提供。患者个体化顾虑是GCs不提供CMA时报告的最大障碍(51%)。

要点

  • 95%(183/192)的遗传咨询师已将染色体微阵列(CMA)纳入临床实践。
  • 64%认为CMA获益大于风险,52%同意无论指征均应提供CMA。
  • 患者个体化顾虑是遗传咨询师不提供CMA时报告的最大障碍(51%)。

核心结论

  • 遗传咨询师在特定指征下遵循CMA使用指南,但在效用尚不明确的常规指征方面需要进一步指南。
  • 作者认为ACOG和SMFM应随着产前CMA在各指征下效用信息的积累继续修订指南。
  • 作者认为像美国遗传咨询师学会(NSGC)这样的组织应考虑发布针对遗传咨询师实践领域的产前CMA指南。

研究设计与样本

  • 基于调查的横断面研究,对象为以英语执业、获得委员会认证或符合资格且目前从事产前遗传咨询的遗传咨询师。

主要发现

  • 192名受访者中183人(95%)已将染色体微阵列(CMA)纳入临床实践。
  • 64%的受访者认为CMA的获益大于风险,52%同意无论指征均应向所有女性提供CMA。
  • 自报对CMA知识为专家/舒适者(85%)及熟悉当前临床指南者(86%)显著更可能对接受侵入性检测的患者及胎儿异常患者提供CMA。
  • 当遗传咨询师不向患者提供CMA时,患者个体化顾虑是报告的最大障碍(51%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We evaluated what prenatal genetic counselor's (GCs) practices, attitudes, and barriers are in regards to prenatal microarray since the publication of the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) guidelines for microarray use. METHODS: This was a survey-based cross-sectional study of English-speaking, board certified or eligible GCs who currently practice prenatal genetic counseling. RESULTS: Of 192 respondents, 183 (95%) have incorporated chromosome microarray (CMA) into clinical practice, with 64% believing that the benefits of CMA outweigh the harms and 52% agreeing that CMA should be offered to all women regardless of indication. Those who reported being experts/comfortable in their knowledge of CMA (85%) and familiar with current clinical guidelines (86%) were significantly more likely to offer CMA to patients undergoing invasive testing and patients with fetal anomalies. Patient-specific concerns were the largest reported barrier (51%) when GCs do not offer CMA to patients. CONCLUSION: Our study demonstrates GCs follow guidelines for CMA use when specific indications are involved, but further guidelines are needed regarding CMA use for other routine indications where utility of CMA is not clearly understood. On this basis, ACOG and SMFM should continue revising their guidelines as more information comes to light regarding utility of prenatal CMA for all indications, and organizations like the National Society of Genetic Counselors (NSGC) should consider publishing guidelines on prenatal CMA that are specialized to the GCs sphere of practice.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Durham L, Papanna R, Stevens B, et al. The utilization of prenatal microarray: A survey of current genetic counseling practices and barriers. Prenat Diagn. 2019. PMID: 30734934. doi:10.1002/pd.5435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。